Vincent Simmon, PhD
About Dr. Simmon
Dr. Vincent Simmon is an accomplished senior executive with broad experience in the biotech industry since 1979. Dr. Simmon was previously the COO of Spinogenix, CEO of Alpha 1 Biomedicals, Cortex Pharmaceuticals, Xytis Inc., and COO of Merrimack Pharmaceuticals. His experience includes leading multinational clinical trials in mild cognitive impairment and traumatic brain injury, Phase 1 and 2 clinical trials in Alzheimer’s disease, schizophrenia, rheumatoid arthritis and psoriasis, as well as clinical trials in AIDS, hepatitis B and hepatitis C. He has negotiated R&D and licensing deals with Organon (ultimately acquired by Merck), Servier, Green Cross and Yoshitomi in Japan, Shire and Pharmacia (acquired by Pfizer).
Dr. Simmon earned his PhD from Brown University in Molecular and Microbiology and received his BA from Amherst College. He was a post-doctoral fellow at Stanford University and received Executive MBA training at Stanford and WR Grace.